You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

COVID-19 Update

Repligen responds to COVID-19: Operations Status

Repligen understands and supports the vital role that our customers fill in the development and manufacture of biological drugs, vaccines and diagnostics.  As a company, we are committed to employee health and safety, and to the continued supply of our products and services to our customers globally.

A cross-functional and multi-site COVID-19 Task Force at Repligen continues to monitor and evaluate the evolving global situation. As a team, we are assessing the latest guidance and facts, and are prioritizing decisions that will protect our employees and ensure that our manufacturing facilities remain open.  If you have specific questions or concerns regarding product supply or technology support, please contact your local Account Manager or our Customer Service team.

July 1, 2022 Update

Manufacturing and Operational Status

To date, our manufacturing facilities and distribution centers are fully operational.  We have recently implemented site visitor restrictions, work from home policies for non-operational staff, enhanced facility cleaning procedures, work cell optimization and personal hygiene training to ensure the protection of our employees, manufacturing centers and distribution networks.  These approaches reduce risk of interruption at our manufacturing centers of excellence and distribution centers.

Commercial and Technical Support

We understand that many of our customers are asking us to restrict non-essential visits. Our customer-facing teams are available and enabled to take orders, answer inquiries, and provide support remotely or in person, as allowed, if the situation requires such support. We have defined our global employee travel guidelines to support all customer facing activities.

Employee and Facility Safety

We are implementing precautionary measures to help protect employees and visitors to our sites. Visitors will be notified of required procedures prior to arriving to a site. Signage at entry ways indicate visitor restrictions and procedures. We have implemented employee travel restrictions to all High-risk Level locations (as defined by the CDC) and a self-isolation decision tree to handle travel and potential exposure situations.

Repligen Named Critical Supplier for COVID-19 Vaccine Development

Repligen was recognized as a critical supplier for COVID-19 vaccine development. The team at the Rancho Dominguez Center of Excellence played a vital role in the successful production of over 500 million COVID-19 vaccines for a major manufacturer. We are proud of the part we play in the effort to end the pandemic.

Spectrum® Hollow Fiber Filters

ProConnex® Flow Paths